JP2020517730A - 心的外傷後ストレス障害を治療するための方法 - Google Patents
心的外傷後ストレス障害を治療するための方法 Download PDFInfo
- Publication number
- JP2020517730A JP2020517730A JP2019559072A JP2019559072A JP2020517730A JP 2020517730 A JP2020517730 A JP 2020517730A JP 2019559072 A JP2019559072 A JP 2019559072A JP 2019559072 A JP2019559072 A JP 2019559072A JP 2020517730 A JP2020517730 A JP 2020517730A
- Authority
- JP
- Japan
- Prior art keywords
- dose
- ptsd
- nalmefene
- symptoms
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000028173 post-traumatic stress disease Diseases 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 15
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims abstract description 25
- 229960005297 nalmefene Drugs 0.000 claims abstract description 25
- 208000024891 symptom Diseases 0.000 claims description 9
- 206010033799 Paralysis Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 230000002996 emotional effect Effects 0.000 claims description 6
- 230000036651 mood Effects 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010012239 Delusion Diseases 0.000 claims description 2
- 206010020400 Hostility Diseases 0.000 claims description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 231100000868 delusion Toxicity 0.000 claims description 2
- 230000008451 emotion Effects 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 206010016754 Flashback Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000012488 Opiate Overdose Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010013461 dissociative amnesia Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heat Treatment Of Articles (AREA)
- Heat Treatment Of Strip Materials And Filament Materials (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
- 心的外傷後ストレス障害(PTSD)と診断された患者を治療するための方法であって、前記方法が、
a)1日当たり100mgの開始用量を、PTSDと診断されたか、又はPTSDの症状を有する患者に投与することと、
b)1日当たり100mgまでの用量を、2〜5日間毎に、最大1日当たり1000mgまで増加させることと、を含む方法。 - 請求項1に記載の方法において、工程a)の前記初期用量が、50mgで1日2回を含む分割用量で投与される方法。
- 請求項1に記載の方法において、工程b)の前記増加用量が、50mgで1日2回の分割用量スケジュールで投与される方法。
- 請求項1に記載の方法において、前記用量が、3〜4日毎に増加される方法。
- 請求項1に記載の方法において、前記PTSDと診断された患者が、前記患者によって体験される前記PTSDの症状を軽減又は逆転させる方法。
- 請求項5に記載の方法において、前記軽減又は逆転される症状が、感情的麻痺、ポジティブな感情を体験することが持続的にできないこと(例えば、幸福、満足、又は愛情を体験することができないこと)、重要な活動への関心又は参加の著しい減退、及び他者から孤立しているか、又は疎外になっている感覚からなる群から選択される方法。
- 請求項1に記載の方法において、前記患者が、ナルメフェンの投与後に、オピオイド離脱症状を体験しない方法。
- 請求項1に記載の方法において、ナルメフェンの前記投与が、変動する気分状態の発生の回避をもたらす方法。
- 請求項8に記載の方法において、前記気分状態が、不安、敵意並びに怒り、うつ、及び妄想症からなる群から選択される方法。
- 請求項1に記載の方法において、前記投与されるナルメフェンが、静脈内注射製剤、筋肉内注射製剤、皮下注射製剤、局所製剤、経皮製剤、及び経口剤形製剤からなる群から選択される剤形で製剤化される方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762489501P | 2017-04-25 | 2017-04-25 | |
US62/489,501 | 2017-04-25 | ||
PCT/US2018/029257 WO2018200607A1 (en) | 2017-04-25 | 2018-04-25 | Method for treating post-traumatic stress disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020517730A true JP2020517730A (ja) | 2020-06-18 |
JP2020517730A5 JP2020517730A5 (ja) | 2021-06-10 |
Family
ID=63918674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019559072A Pending JP2020517730A (ja) | 2017-04-25 | 2018-04-25 | 心的外傷後ストレス障害を治療するための方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10987350B2 (ja) |
EP (1) | EP3615012B1 (ja) |
JP (1) | JP2020517730A (ja) |
AU (1) | AU2018258337A1 (ja) |
CA (1) | CA3061350A1 (ja) |
IL (1) | IL270203B2 (ja) |
MX (1) | MX2019012840A (ja) |
WO (1) | WO2018200607A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
WO1997033581A1 (en) * | 1996-03-13 | 1997-09-18 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US20160058754A1 (en) * | 2013-04-17 | 2016-03-03 | H. Lundbeck A/S | Nalmefene for Treatment of Patients with Anxiety Disorder |
-
2018
- 2018-04-25 JP JP2019559072A patent/JP2020517730A/ja active Pending
- 2018-04-25 IL IL270203A patent/IL270203B2/en unknown
- 2018-04-25 WO PCT/US2018/029257 patent/WO2018200607A1/en unknown
- 2018-04-25 AU AU2018258337A patent/AU2018258337A1/en not_active Abandoned
- 2018-04-25 CA CA3061350A patent/CA3061350A1/en active Pending
- 2018-04-25 US US16/608,162 patent/US10987350B2/en active Active
- 2018-04-25 EP EP18789794.7A patent/EP3615012B1/en active Active
- 2018-04-25 MX MX2019012840A patent/MX2019012840A/es unknown
Non-Patent Citations (1)
Title |
---|
THE ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, vol. 30, no. 4, JPN6022002211, 1993, pages 255 - 263, ISSN: 0005118583 * |
Also Published As
Publication number | Publication date |
---|---|
IL270203A (ja) | 2019-12-31 |
US20200197387A1 (en) | 2020-06-25 |
AU2018258337A1 (en) | 2019-12-12 |
IL270203B2 (en) | 2023-11-01 |
EP3615012A1 (en) | 2020-03-04 |
CA3061350A1 (en) | 2018-11-01 |
MX2019012840A (es) | 2020-07-20 |
WO2018200607A1 (en) | 2018-11-01 |
IL270203B1 (en) | 2023-07-01 |
EP3615012A4 (en) | 2020-12-23 |
US10987350B2 (en) | 2021-04-27 |
EP3615012B1 (en) | 2024-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009201019B2 (en) | Dosage form containing oxycodone and naloxone | |
US9198889B2 (en) | Methods for treating post-traumatic stress disorder | |
JP7153950B2 (ja) | 神経発達障害療法 | |
JP7198197B2 (ja) | 睡眠障害の治療及び予防 | |
KR20080021139A (ko) | 편두통을 위한 드로나비놀 치료 | |
ES2775425T3 (es) | Procedimiento de tratamiento del síndrome de Prader-Willi | |
JP2008201799A (ja) | コカイン依存症治療用薬剤 | |
ES2337622T3 (es) | Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos. | |
JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
Pang et al. | Metoclopramide decreases emesis but increases sedation in tramadol patient-controlled analgesia | |
JP2020517730A (ja) | 心的外傷後ストレス障害を治療するための方法 | |
Saxon et al. | Co-occurring substance use disorders and PTSD. | |
TW201211021A (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
CN111601591A (zh) | 睡眠障碍的治疗和预防 | |
JP2005132799A (ja) | 本態性振戦の予防・治療剤 | |
Hariharan et al. | Update on opioid addiction for perioperative and critical unit care: anaesthesiologists perspective | |
WO2015160249A2 (en) | Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation | |
IsHak et al. | Overview of approved psychiatric medications 2008-2023: A systematic review | |
Mohamad et al. | Variability of plasma methadone concentration in opiate dependent receiving methadone: A personalised approach towards optimizing dose | |
JP6419780B2 (ja) | 睡眠障害患者の治療のためのナルメフェン | |
JP2020517730A5 (ja) | ||
Strain et al. | Pharmacology and clinical use of LAAM, clonidine, and lofexidine | |
FIER et al. | Convulsive seizures in chlorprothixene overdose | |
Galant | Therapeutic Options in Smoking Cessation | |
TW201023853A (en) | Method of treating sleep disorders using eplivanserin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210423 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210423 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20211227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211227 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231031 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240412 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240611 |